Brensocatib Leads to Lower Rate of Pulmonary Exacerbations in Bronchiectasis
By Elana Gotkine HealthDay Reporter
THURSDAY, April 24, 2025 -- For patients with bronchiectasis, brensocatib leads to a lower annualized rate of pulmonary exacerbations, according to a study published in the April 24 issue of the New England Journal of Medicine.
James D. Chalmers, M.B., Ch.B., Ph.D., from the University of Dundee in the United Kingdom, and colleagues conducted a phase 3, double-blind trial involving patients with bronchiectasis who were randomly assigned to receive brensocatib (10 mg or 25 mg once per day) or placebo (1:1:1 ratio for adults; 2:2:1 ratio for adolescents).
A total of 1,680 adults and 41 adolescents were randomly assigned to brensocatib or placebo. The researchers found that the annualized rate of pulmonary exacerbations was 1.02, 1.04, and 1.29 in the 10-mg brensocatib group, 25-mg brensocatib group, and placebo group, respectively (rate ratios, 0.79 and 0.81 with the 10-mg and 25-mg brensocatib doses, respectively, versus placebo). For the time to first exacerbation, the hazard ratio was 0.81 and 0.83 with the 10-mg and 25-mg doses, respectively. At week 52, 48.5 percent of patients in each brensocatib group remained exacerbation-free, compared with 40.3 percent in the placebo group (rate ratios, 1.20 and 1.18 with the 10-mg and 25-mg doses, respectively). Forced expiratory volume in one second had decreased by 50, 24, and 62 mL with the 10-mg dose, 25-mg dose, and placebo, respectively, at week 52, with the reduction significant for the 25-mg dose. The incidence of adverse events was similar across groups. There was a higher incidence of hyperkeratosis with brensocatib.
"These results show that inhibiting dipeptidyl peptidase 1 with brensocatib -- and thereby targeting neutrophilic inflammation -- results in meaningful improvements in outcomes in patients with bronchiectasis," the authors write.
The study was funded by Insmed, which is developing brensocatib.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted April 2025
Read this next
Consistent Physical Activity Linked to Reduced All-Cause, CVD Mortality
FRIDAY, July 11, 2025 -- Consistently and increasingly accumulated physical activity (PA) is associated with a reduced risk for all-cause and cardiovascular disease (CVD)...
Increased Liver Enzyme Levels Seen With Use of Cannabidiol in Adults
THURSDAY, July 10, 2025 -- Use of cannabidiol (CBD) within the range consumers are taking with unregulated CBD products is associated with increased liver enzyme levels, according...
Majority of Patients With Lyme Disease Do Not Follow Up With Clinician
THURSDAY, July 10, 2025 -- Only 34 percent of patients with erythema migrans >5 cm are positive for Lyme disease by a standard two-tier testing (STTT) algorithm, and of...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.